A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors (Q34352278)

1 August 2017

title

A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors (English)

1 reference

1 August 2017

1 reference

Charles J Nock

1

1 reference

1 August 2017

Joanna M Brell

2

1 reference

1 August 2017

Joseph A Bokar

3

1 reference

1 August 2017

Matthew M Cooney

4

1 reference

1 August 2017

Brenda Cooper

5

1 reference

1 August 2017

Joseph Gibbons

6

1 reference

1 August 2017

Smitha Krishnamurthi

7

1 reference

1 August 2017

Sudhir Manda

8

1 reference

1 August 2017

Panayiotis Savvides

9

1 reference

1 August 2017

Scot C Remick

10

1 reference

1 August 2017

Percy Ivy

11

1 reference

1 August 2017

Afshin Dowlati

12

1 reference

1 August 2017

language of work or name

1 reference

23 September 2009

1 reference

Investigational New Drugs

1 August 2017

published in

1 reference

1 August 2017

volume

29

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

126-130

1 reference

Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199744

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199744

Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199744

Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199744

Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199744

Oxaliplatin: available data in non-colorectal gastrointestinal malignancies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199744

Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199744

Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199744

DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199744

Production and biological activity of rebeccamycin, a novel antitumor agent.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199744

Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199744

A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19774342

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Water soluble derivatives of rebeccamycin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19774342

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-009-9322-9

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference

1 August 2017

1 reference